EOLS / Evolus, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 EVOLUS, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number

Amended and Restated Loan Agreement, dated as of May 5, 2025, by and among Evolus, Inc. (as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates •Global Net Revenue of $69.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 EVOLUS, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

  Evolus Announces Departure of its Chief Financial Officer

  Evolus Announces Departure of its Chief Financial Officer NEWPORT BEACH, Calif., May 27, 2025 – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has resigned effective June 13, 2025, to accept the same position at a private mental health and wellness techn

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, I

Evolus Reports First Quarter 2025 Results

Evolus Reports First Quarter 2025 Results •Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 •Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market •GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 EVOLUS, INC. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number) (

  Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility Refinanced Existing Credit Facility Drawing $150 Million at Close with $100 Million of Strategic Incremental Capacity

    Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility Refinanced Existing Credit Facility Drawing $150 Million at Close with $100 Million of Strategic Incremental Capacity NEWPORT BEACH, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 EVOLUS, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

Evolus Reports Record Fourth Quarter and Full Year 2024 Financial Results; Reaffirms 2025 Guidance

Evolus Reports Record Fourth Quarter and Full Year 2024 Financial Results; Reaffirms 2025 Guidance •Global Net Revenue Record of $79.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Evolus, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1385614 (State or other jurisdiction of

As filed with the Securities and Exchange Commission on March 4, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Evolus, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1385614 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Id

Second Amendment to Stock Purchase Agreement, dated as of December 14, 2017, by and among SCH-AEON, LLC (f/k/a Strathspey Crown Holdings, LLC), ALPHAEON Corporation, the Registrant and J. Christopher Marmo, as Contributors’ Representative, and acknowledged by the parties listed as Contributors on the signature pages thereto.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Registrant and 520 Newport Center Drive LLC

SECOND AMENDMENT TO LEASE I.PARTIES AND DATE. This Second Amendment to Lease (“Amendment”) dated October 16, 2024, by and between 520 NEWPORT CENTER DRIVE LLC, a Delaware limited liability company (“Landlord”), and EVOLUS, INC., a Delaware corporation (“Tenant”). II.RECITALS. Landlord and Tenant entered into a lease dated May 15, 2019, which lease was amended by First Amendment to Lease dated July

First Amendment to the Evolus, Inc. 2023 Inducement Incentive Plan

FIRST AMENDMENT TO THE EVOLUS, INC. 2023 INDUCEMENT INCENTIVE PLAN This First Amendment (this “First Amendment”) to the Evolus, Inc. 2023 Inducement Incentive Plan (the “Plan”) is adopted by the Board of Directors (the “Board”) of Evolus, Inc., a Delaware corporation (the “Company”), on December 12, 2024. RECITALS A. The Company currently maintains the Plan. B. Pursuant to Section 5.2 of the Plan,

List of Subsidiaries.

Exhibit 21.1 EVOLUS, INC. LIST OF SUBSIDIARIES Name of Subsidiary Jurisdiction of Incorporation or Organization Evolus Pharma Limited Ireland Evolus Pharma BV Netherlands Evolus International Ltd. United Kingdom Evolus GmbH Germany Evolus Australia Pty Ltd Australia Evolus-Pharma Spain SL Spain Evolus New Zealand Limited New Zealand

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, INC. (Exact name

Exhibit 19

EVOLUS, INC. INSIDER TRADING POLICY The United States federal and state securities laws prohibit certain persons who possess material nonpublic information about a company from buying or selling securities of that company or for giving such information (“tipping”) to another person who may trade on the basis of that information. Therefore, Evolus, Inc., a Delaware corporation (the “Company”), has

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Evolus, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.00001 pe

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance Expects U.S. Approval Within 90 Days for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Aci

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance Expects U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 EVOLUS, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numb

December 12, 2024

December 12, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Mail Stop 3561 100 F. Street, N.E. Washington, D.C. 20549 Attn: Tara Harkins Re: Evolus, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 Form 8-K filed on November 6, 2024 File No. 001-38381 On behalf of Evolus, Inc., a Delaware corporation (the “Company”), this letter

EOLS / Evolus, Inc. / TANG CAPITAL MANAGEMENT LLC - AMENDMENT NO. 2 Passive Investment

SC 13G/A 1 eols1015242sc13ga2.htm AMENDMENT NO. 2 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Evolus, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 30052C107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appr

EOLS / Evolus, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d912036dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Evolus, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 30052C107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the

JOINT FILING AGREEMENT

EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.00001 par value per share, of Evolus, Inc. and further agree to the filing of this agre

EOLS / Evolus, Inc. / Stonepine Capital Management, LLC Passive Investment

SC 13G/A 1 eols13ga2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Evolus, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 30052C107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Evolus, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.00001 pe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Evolus, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1385614 (State or other jurisdiction of

As filed with the Securities and Exchange Commission on November 6, 2024 Registration No.

Evolus Reports Third Quarter 2024 Results

Evolus Reports Third Quarter 2024 Results •Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33% •Received Approval for Estyme® Injectable Hyaluronic Acid (HA) Gels in the European Union; Experience Program to Launch Immediately with Full Launch Expected in the Second Half of 2025 •Premarket Approval (PMA) Application for Evolysse™ Form and Evolysse™ Smoot

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLU

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numb

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, IN

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance •Total Net Revenue of $66.

Evolus Announces Appointment of Albert G. White III to Board of Directors

Evolus Announces Appointment of Albert G. White III to Board of Directors NEWPORT BEACH, Calif., July 1, 2024 – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effe

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

024 Employee Stock Purchase Plan

EVOLUS, INC. 2024 EMPLOYEE STOCK PURCHASE PLAN 1.PURPOSE The purpose of this Plan is to assist Eligible Employees in acquiring a stock ownership interest in the Corporation, at a favorable price and upon favorable terms, pursuant to a plan which is intended to qualify as an “employee stock purchase plan” under Section 423 of the Code. This Plan is also intended to encourage Eligible Employees to r

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

Evolus Reports First Quarter 2024 Results and Provides Business Update

Evolus Reports First Quarter 2024 Results and Provides Business Update •Q1 2024 Net Revenue of $59.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, I

, by and between Daewoong Pharmaceutical Co. Ltd. and Evolus, Inc.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2024 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

ting Agreement, dated March 11, 2024, by and between Evolus, Inc. and Leerink Partners, LLC and Stifel, Nicolaus & Company, Incorporated.

Exhibit 1.1 EVOLUS, INC. (a Delaware corporation) 3,554,000 Shares of Common Stock UNDERWRITING AGREEMENT March 11, 2024 Leerink Partners LLC Stifel, Nicolaus & Company, Incorporated as Representatives of the several Underwriters c/o Leerink Partners LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o Stifel, Nicolaus & Company, Incorporated 787 Seventh Avenue, 32nd Floor New York, New

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number

3,554,000 shares Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-270370 PROSPECTUS SUPPLEMENT (to Prospectus dated June 8, 2023) 3,554,000 shares Common Stock This is an underwritten offering of 3,554,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Market, or Nasdaq, under the trading symbol “EOLS.” On March 8, 2024, the last reported sale price of our common stock on Nasdaq w

List of Subsidiaries.

Exhibit 21.1 EVOLUS, INC. LIST OF SUBSIDIARIES Name of Subsidiary Jurisdiction of Incorporation or Organization Evolus Pharma Limited Ireland Evolus Pharma BV Netherlands Evolus International Ltd. United Kingdom Evolus GmbH Germany Evolus Australia Pty Ltd Australia

First Amendment to Lease, dated as of July 27, 2023, by and between the Registrant and 520 Newport Center Drive LLC

FIRST AMENDMENT TO LEASE I. PARTIES AND DATE. This First Amendment to Lease (“Amendment”) is made and dated as of July 27, 2023, by and between 520 NEWPORT CENTER DRIVE LLC, a Delaware limited liability company (“Landlord”), and EVOLUS, INC., a Delaware corporation (“Tenant”). II. RECITALS. Landlord and Tenant entered into an office space lease dated May 15, 2019 (the “Lease”) for space consisting

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

First Amendment to License and Supply Agreement, dated as of February 26, 2014, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Evolus, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.00001 pe

Policy Regarding the Recoupment of Certain Compensation Payments

Policy Regarding the Recoupment of Certain Compensation Payments As adopted by the Board of Directors on December 1, 2023 In the event Evolus, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Evolus, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1385614 (State or other jurisdiction of

As filed with the Securities and Exchange Commission on March 7, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Evolus, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1385614 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Id

description of the Company’s Common Stock contained in

Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following is a summary of the rights of our common stock and preferred stock, certain provisions of our certificate of incorporation and our bylaws, and applicable law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and bylaws, copies of which are filed as exhibits to o

, and Distribution Agreement (Europe), dated as of December 20,

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Amendment to Stock Purchase Agreement, dated as of September 30, 2014, by and between Strathspey Crown Holdings, LLC and ALPHAEON Corporation.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Stock Purchase Agreement, dated as of September 30, 2014, by and between Strathspey Crown Holdings, LLC and ALPHAEON Corporation.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance

Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance •Generated $0.

Second Amendment to License and Supply Agreement, dated as of July 15, 2014, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, INC. (Exact name

EOLS / Evolus, Inc. / Nantahala Capital Management, LLC - SC 13G Passive Investment

SC 13G 1 tm243309d15sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EVOLUS, INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 30052C107 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appro

AGREEMENT

EX-99.1 2 d651705dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2

EOLS / Evolus, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d651705dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Evolus, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 30052C107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the

EOLS / Evolus, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment

Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

EOLS / Evolus, Inc. / Stonepine Capital Management, LLC Passive Investment

SC 13G/A 1 eols13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Evolus, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 30052C107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

EOLS / Evolus, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SC 13G 1 tv0890-evolusinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Evolus Inc Title of Class of Securities: Common Stock CUSIP Number: 30052C107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedu

EOLS / Evolus, Inc. / FIRST MANHATTAN CO Passive Investment

SC 13G/A 1 firstmanhattan-eols123123a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Evolus, Inc. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 30052C107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropri

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numb

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations Issues 2024 Guidance

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations Issues 2024 Guidance •Preliminary Unaudited Net Revenue of Approximately $61 Million for the Fourth Quarter 2023, Representing 40% Growth Over the Prior Year Quarter and a 22% Increase Over the Prior Sequential Quarter •Preliminary Unaudited Net Revenue of Approximately $202 Million for the Full-Year 2023, Representing 36% Growth Over the Prior Year •2024 Net Revenue Guidance of $255 Million to $265 Million, Which Represents 26% to 31% Growth From Preliminary 2023 Results NEWPORT BEACH, Calif.

Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe •Exclusive Distributor Agreement with Symatese Broadens Evolus’ Dermal Filler Footprint Beyond the U.S. to Include the United King

Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe •Exclusive Distributor Agreement with Symatese Broadens Evolus’ Dermal Filler Footprint Beyond the U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 EVOLUS, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Num

EOLS / Evolus Inc / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment

SC 13G 1 d802017dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Evolus, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 30052C107 (CUSIP Number) November 15, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropri

Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®

Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau® •Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022 •Raises Full-Year 2023 Net Revenue Guidance from $185 to $195 Million to $194 to $198 Million •Operating Use of Cash in Q3 of $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLU

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numb

Employment Agreement, dated August 21, 2023, by and between Tomoko Yamagishi-Dressler and the Registrant.

EMPLOYMENT AGREEMENT This Employment Agreement is between Evolus, Inc., a Delaware corporation (the “Company”), and Tomoko Yamagishi-Dressler, an individual (“Employee”). This Agreement is entered into effective as of August 21, 2023 (the “Effective Date”). 1.POSITION AND RESPONSIBILITIES a.Position. Employee shall be employed by the Company to render services to the Company in the position of Chi

EOLS / Evolus Inc / Medytox Inc. - AMENDMENT TO FORM SC 13G Passive Investment

SC 13G/A 1 medytox-sc13ga101623.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Evolus, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 30052C107 (CUSIP Number) October 16, 2023 (Date of Event Which Requires Filing of this St

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Evolus, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1385614 (State or other jurisdiction of

As filed with the Securities and Exchange Commission on October 6, 2023 Registration No.

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Evolus, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.00001 pe

2023 Inducement Incentive Plan

EVOLUS, INC. 2023 INDUCEMENT INCENTIVE PLAN Evolus, Inc. sets forth herein the terms and conditions of its 2023 Inducement Incentive Plan. 1.PURPOSE The Plan is intended to enhance the Company’s and its Affiliates’ ability to attract and retain employees and Non-Employee Directors, and to motivate such employees and Non-Employee Directors to serve the Company and its Affiliates and to expend maxim

EOLS / Evolus Inc / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

EOLS / Evolus Inc / Alphaeon 1 LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Evolus, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 30052C107 (CUSIP Num

Power of Attorney of Alphaeon 1 LLC

EXHIBIT 24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Andrew Lusk, and Jared Klumker or either of them signing individually, the undersigned's true and lawful attorney-in-fact (each, an “Attorney-in-Fact”) to: (1) complete and execute, for and on behalf of the undersigned, in the undersigned’s capacity as a beneficial owner of more than ten percent (10%) of any equity securities of Evolus, Inc.

Form of First Amendment to Warrant Agreement, by and between Alphaeon 1 LLC and each of the Noteholders.

EXHIBIT 1 * Portions of this exhibit have been excluded because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed.

License, Supply, and Distribution Agreement, dated as of May 9, 2023 by and between Symatese S.A.S. and the Registrant

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Evolus Reports Second Quarter 2023 Results and Provides Business Update •Q2 2023 Net Revenue of $49.3 Million, Up 33% from Q2 2022 •Raises Full-Year 2023 Net Revenue Guidance to $185 to $195 Million •On Track to Achieving Sustained Profitability With

Evolus Reports Second Quarter 2023 Results and Provides Business Update •Q2 2023 Net Revenue of $49.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, IN

Third Amendment to Loan Agreement, dated as of May 9, 2023, by and among Evolus, Inc. (as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number

Fifth Amendment to Supply Agreement, dated as of April 20, 2023, by and between Daewoong Pharmaceutical Co. Ltd. and Evolus, Inc.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue •Company Increases Full-Year 2023 Net Revenue Guidance to $185 to $195 Million •Company Achieved Quarterly Net Revenue of $49.3 Million, Growing 33% Year-over-Year and 10

Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue •Company Increases Full-Year 2023 Net Revenue Guidance to $185 to $195 Million •Company Achieved Quarterly Net Revenue of $49.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 EVOLUS, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

EOLS / Evolus Inc / Stonepine Capital Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Evolus, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 30052C107 (CUSIP Number) June 19, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 EVOLUS, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated June 12, 2023

CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EVOLUS, INC.

Up to $50,000,000 Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-270370 PROSPECTUS Up to $50,000,000 Common Stock We have entered into a sales agreement, the Sales Agreement, with SVB Securities LLC, or SVB Securities, relating to the sale of our common stock offered by this prospectus. In accordance with the terms of the Sales Agreement, under this prospectus we may offer and sell our comm

As filed with the Securities and Exchange Commission on June 7, 2023

As filed with the Securities and Exchange Commission on June 7, 2023 Registration No.

Evolus, Inc. 520 Newport Center Dr., Suite 1200 Newport Beach, CA 92660

Evolus, Inc. 520 Newport Center Dr., Suite 1200 Newport Beach, CA 92660 June 7, 2023 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Laura Crotty Re: Request for Effectiveness for Evolus, Inc. Registration Statement on Form S-3 (File No. 333-270370) Dear Ms. Crotty: Pursuant

EOLS / Evolus Inc / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) EVOLUS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 30052C107 (CUSIP Number) MAY 8, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant t

Evolus Reports First Quarter 2023 Results and Provides Business Update •Q1 2023 Net Revenue of $41.7 Million, Up 23% from Q1 2022 •Reaffirms Full-Year 2023 Net Revenue Guidance of $180 to $190 Million •Raises 2028 Revenue Outlook from $500 Million to

Evolus Reports First Quarter 2023 Results and Provides Business Update •Q1 2023 Net Revenue of $41.

Evolus Announces Expansion into U.S. Dermal Filler Market with EvolysseTM, a First-Generation Cold Technology HA by Symatese •Portfolio of 5 Fillers in Late-Stage Development; First Approval Expected in 1H 2025 •Raises 2028 Revenue Outlook from $500

Evolus Announces Expansion into U.S. Dermal Filler Market with EvolysseTM, a First-Generation Cold Technology HA by Symatese •Portfolio of 5 Fillers in Late-Stage Development; First Approval Expected in 1H 2025 •Raises 2028 Revenue Outlook from $500 Million to $700 Million Representing a 29% CAGR •Highly Capital Efficient Deal Structure Funded Through $50 Million Pharmakon Tranche; Company Expects

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ý Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State

As filed with the Securities and Exchange Commission on April 14, 2023

As filed with the Securities and Exchange Commission on April 14, 2023 Registration No.

O’Melveny & Myers LLP

O’Melveny & Myers LLP 610 Newport Center Drive 17th Floor Newport Beach, CA 92660 T: +1 949 823 7968 omm.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 EVOLUS, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number

Sales Agreement, dated March 8, 2023, by and between Evolus, Inc. and SVB Securities LLC as Sales Agent

Exhibit 1.2 Execution Version EVOLUS, INC. Shares of Common Stock ($0.00001 par value per share) SALES AGREEMENT March 8, 2023 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Evolus, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows: 1. Issuance and Sale

List of Subsidiaries.

Exhibit 21.1 EVOLUS, INC. LIST OF SUBSIDIARIES Name of Subsidiary Jurisdiction of Incorporation or Organization Evolus Pharma Limited Ireland Evolus Pharma BV Netherlands Evolus International Ltd. United Kingdom Evolus GmbH Germany Evolus Australia Pty Ltd Australia

Exhibit 4.3

Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following is a summary of the rights of our common stock and preferred stock, certain provisions of our certificate of incorporation and our bylaws, and applicable law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and bylaws, copies of which are filed as exhibits to o

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Evolus, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.00001 pe

Form of Indenture

Exhibit 4.4 EVOLUS, INC. Issuer AND as Trustee INDENTURE Dated as of , 20 Debt Securities CROSS-REFERENCE TABLE(1) SECTION OF TRUST INDENTURE ACT OF 1939, AS AMENDED SECTION(S) OF INDENTURE 310(a) 7.9 310(b) 7.8 311(a) 7.13 311(b) 7.13 312(a) 5.1, 5.2(a) 312(b) 5.2(b) 312(c) 5.2(c) 313(a) 5.4(a) 313(b) 5.4(b) 313(c) 5.4(c) 313(d) 5.4 314(a) 5.3, 14.12 314(c) 14.7(a) 314(e) 14.7(b) 315(a) 7.1 315(b

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-3 EVOLUS, INC.

Form of Performance Restricted Stock Unit Agreement

PERFORMANCE RSU AWARD AGREEMENT EVOLUS, INC. 2017 OMNIBUS INCENTIVE PLAN Evolus, Inc. (the “Company”) grants to the Grantee named below (“you”) the number of performance-based vesting restricted stock units (“RSUs”) set forth below (the “Award”). Plan: Evolus, Inc. 2017 Omnibus Incentive Plan Defined Terms: As set forth in the Plan, unless otherwise defined in this Agreement Grantee: [Name] Grant

Power of Attorney (included on signature page).

As filed with the Securities and Exchange Commission on March 8, 2023 Registration No.

License and Supply Agreement, dated as of September 30, 2013, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.

Exhibit 10.3 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”. LICENSE & SUPPLY AGREEMENT THIS LICENSE AND SUPPLY AGREEMENT (hereinafter this “Agreement”) is entered into this 30th day of September, 2013 (the “Effective Date”),

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, INC. (Exact name

Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update •Q4 2022 Net Revenue Reached an All-Time High of $43.6 Million, Up 26% from Q4 2021 •Full-Year 2022 Net Revenue of $148.6 Million, Up 49% Over 2021 •Reaffirms Full-

Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update •Q4 2022 Net Revenue Reached an All-Time High of $43.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 EVOLUS, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Evolus, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1385614 (State or other jurisdiction of

As filed with the Securities and Exchange Commission on March 8, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Evolus, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1385614 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Id

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.00001 par value per share, of Evolus, Inc. and further agree to the filing of this agreement as an exhibit thereto. In a

EOLS / Evolus Inc / TANG CAPITAL PARTNERS LP Passive Investment

Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

EOLS / Evolus Inc / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 EVOLUS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 30052C107 (CUSIP Number) FEBRUARY 6, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this

EOLS / Evolus Inc / FIRST MANHATTAN CO Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

EOLS / Evolus Inc / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

EOLS / Evolus Inc / Medytox Inc. - AMENDMENT TO FORM SC 13G Passive Investment

SC 13G/A 1 medytox-sc13ga020123.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Evolus, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 30052C107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this S

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numb

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration •Q4 2022 Preliminary Unaudited Net Revenue of Approximately

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration •Q4 2022 Preliminary Unaudited Net Revenue of Approximately $43.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Num

Fourth Amendment to Supply Agreement, dated December 12, 2022, by and between Evolus, Inc. and Daewoong Pharmaceutical Co. Ltd.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.

Evolus Extends Term of Credit Facility with Pharmakon Advisors •Second Tranche of $50 Million Now Available Until December 31, 2023, Providing Continued Financial Flexibility •All Other Facility Terms and Conditions Remain Unchanged •Company Continue

Evolus Extends Term of Credit Facility with Pharmakon Advisors ?Second Tranche of $50 Million Now Available Until December 31, 2023, Providing Continued Financial Flexibility ?All Other Facility Terms and Conditions Remain Unchanged ?Company Continues to Expect Existing Cash to Fund Current Operations Through Breakeven NEWPORT BEACH, Calif.

Second Amendment to Loan Agreement, dated as of December 5, 2022, by and among Evolus, Inc. (as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).

Exhibit 10.1 SECOND AMENDMENT TO LOAN AGREEMENT This SECOND AMENDMENT TO LOAN AGREEMENT (this ?Amendment?), dated and effective as of December 5, 2022 (the ?Effective Date?), is made by and among EVOLUS, INC., a Delaware corporation (as ?Borrower? and a Credit Party), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as th

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numb

Employment Agreement, dated September 5, 2022, by and between Sandra Beaver and the Registrant.

EMPLOYMENT AGREEMENT This Employment Agreement is between Evolus, Inc., a Delaware corporation (the ?Company?), and Sandra Beaver, an individual (?Employee?). This Agreement is entered into effective as of September 5, 2022 (the ?Effective Date?). 1.POSITION AND RESPONSIBILITIES a.Position. Employee shall be employed by the Company to render services to the Company in the position of Chief Financi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLU

Evolus Reports Third Quarter 2022 Results and Provides Business Update •Reported Sales Up 27% to $33.9 Million; Success of 'Switch Your Tox' Promotion Contributes to $3.5 Million Incremental Increase in Deferred Revenue Over Q2 and Understates Streng

Evolus Reports Third Quarter 2022 Results and Provides Business Update ?Reported Sales Up 27% to $33.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Evolus, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1385614 (State or other jurisdiction of

As filed with the Securities and Exchange Commission on September 9, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Evolus, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1385614 (State or other jurisdiction of incorporation or organization) (I.R.S. Employe

Filing fee table

EX-FILING FEES 2 feetables820221.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Evolus, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registr

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numbe

Evolus Appoints Sandra Beaver as Chief Financial Officer

Evolus Appoints Sandra Beaver as Chief Financial Officer NEWPORT BEACH, Calif., August. 30, 2022 ? Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has named Sandra Beaver as its Chief Financial Officer, effective September 5, 2022. Ms. Beaver brings more than 20 years of financial experience, driving company gr

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number

First Amendment to Loan Agreement, dated April 5, 2022, by and among Evolus, Inc. (as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).

FIRST AMENDMENT TO LOAN AGREEMENT This FIRST AMENDMENT TO LOAN AGREEMENT (this “Amendment”), dated and effective as of April 5, 2022 (the “Effective Date”), is made by and among EVOLUS, INC.

Amended and Restated Employment Agreement, dated August 1, 2022, by and between Evolus, Inc. and Rui Avelar, M.D.

AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement is between Evolus, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, IN

Separation Agreement and General Release of Claims, dated May 3, 2022, by and between Evolus, Inc. and Lauren Silvernail

SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS By signing this Separation Agreement and General Release of Claims (this “Agreement”), I, Lauren Silvernail (hereafter “Employee,” “Me,” “My,” or “I”), acknowledge that Evolus, Inc.

Amendment to Employment Agreement, dated August 1, 2022, by and between Evolus, Inc. and David Moatazedi

AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (this “Amendment”) is between Evolus, Inc.

Evolus Reports Second Quarter 2022 Results and Provides Business Update •Q2 2022 Net Revenue of $37.2 Million, Up 42% from Q2 2021 •Reaffirms Full-Year 2022 Net Revenue Guidance of Upper End of $143 to $150 Million •European Launch to Commence in Q3

Evolus Reports Second Quarter 2022 Results and Provides Business Update ?Q2 2022 Net Revenue of $37.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

EOLS / Evolus Inc / Flynn James E Passive Investment

SC 13G 1 e621734sc13g-evolus.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * Evolus, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 30052C107 (CUSIP Number) May 25, 2022 (Date of Ev

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

Evolus Reports First Quarter 2022 Results and Provides Business Update •Q1 2022 Net Revenue of $33.9 Million, Up 177% from Q1 2021 •Now Guiding to Upper End of Full-Year 2022 Net Revenue of $143 to $150 Million •Reiterating Full-Year non-GAAP Operati

Evolus Reports First Quarter 2022 Results and Provides Business Update ?Q1 2022 Net Revenue of $33.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, I

Separation Agreement and General Release of Claims, dated as of March 3, 202

SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS By signing this Separation Agreement and General Release of Claims (this ?Agreement?), I, Lauren Silvernail (hereafter ?Employee,? ?Me,? ?My,? or ?I?), acknowledge that Evolus, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Evolus, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities Security type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.00001 pe

Form of Inducement Stock Option Award Agreement

OPTION AWARD AGREEMENT EVOLUS, INC. (INDUCEMENT GRANT) Evolus, Inc. (the ?Company?) grants to the Grantee named below (?Grantee? or ?you?) a Nonstatutory Stock Option to purchase the number of Shares set forth below (the ?Option?). Defined Terms: Capitalized terms have the meanings set forth in Exhibit A hereto, unless otherwise defined in this Agreement Grantee: [] Type of Option: Nonstatutory St

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Evolus, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1385614 (State or other jurisdiction of

As filed with the Securities and Exchange Commission on March 4, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Evolus, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1385614 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Id

Evolus Announces Retirement of Chief Financial Officer Lauren Silvernail

Evolus Announces Retirement of Chief Financial Officer Lauren Silvernail NEWPORT BEACH, Calif.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

Form of Inducement Restricted Stock Unit Award Agreement

RSU AWARD AGREEMENT EVOLUS, INC. (INDUCEMENT GRANT) Evolus, Inc. (the ?Company?) grants to the Grantee named below (?Grantee? or ?you?) the number of restricted stock units (?RSUs?) set forth below (the ?Award?). Defined Terms: Capitalized terms have the meanings set forth in Exhibit A hereto, unless otherwise defined in this Agreement Grantee: [] Grant Date: [] (the ?Grant Date?) Number of RSUs G

Evolus Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update •Q4 2021 Net Revenue of $34.7 Million, Up 68% from Q4 2020 •Full-Year 2021 Net Revenue of $99.7 Million, Up 76% Over 2020 •Full-Year 2022 Net Revenue Guidance of $1

Evolus Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update ?Q4 2021 Net Revenue of $34.

Exhibit 4.3 to the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2021, filed with the Commission on March 3, 2022 (each, Commission File No. 001-38381), and any other amendment or report filed for the purpose of updating such description

Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following is a summary of the rights of our common stock and preferred stock, certain provisions of our certificate of incorporation and our bylaws, and applicable law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and bylaws, copies of which are filed as exhibits to o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, INC. (Exact name

Employment Agreement, dated February 25, 2021, by and between Crystal Muilenburg and the Registrant.

EMPLOYMENT AGREEMENT This Employment Agreement is between Evolus, Inc., a Delaware corporation (the ?Company?), and Crystal Muilenburg, an individual (?Employee.?) This Agreement is entered into effective as of February 25, 2021 (the ?Effective Date?). This Agreement amends and restates the terms of the Offer Letter, dated February 20, 2019, between Employee and the Company. 1.POSITION AND RESPONS

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

List of Subsidiaries.

Exhibit 21.1 EVOLUS, INC. LIST OF SUBSIDIARIES Name of Subsidiary Jurisdiction of Incorporation or Organization Evolus Pharma Limited Ireland Evolus Pharma BV Netherlands Evolus International Ltd. United Kingdom

EOLS / Evolus Inc / FIRST MANHATTAN CO Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

EOLS / Evolus Inc / Medytox Inc. - FORM SC 13G/A Passive Investment

7,4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Evolus, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 30052C107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numb

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance •Q4 2021 Preliminary Unaudited Net Revenue of Approximately $34.7 Million, Up 68% from Q4 2020 •Full-Year 2021 Preliminary Unaudited Net R

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance ?Q4 2021 Preliminary Unaudited Net Revenue of Approximately $34.

Evolus Expands Board of Directors with Appointment of Digital and Beauty Innovator Brady Stewart

Evolus Expands Board of Directors with Appointment of Digital and Beauty Innovator Brady Stewart NEWPORT BEACH, Calif.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numbe

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Num

Evolus Enters Into $125 Million Credit Facility with Pharmakon Advisors •Initial Draw of $75 Million Expected to Fund Company Beyond Cash Flow Breakeven •Second Draw of $50 Million Provides Financial Flexibility for Potential Strategic Transactions

Evolus Enters Into $125 Million Credit Facility with Pharmakon Advisors ?Initial Draw of $75 Million Expected to Fund Company Beyond Cash Flow Breakeven ?Second Draw of $50 Million Provides Financial Flexibility for Potential Strategic Transactions NEWPORT BEACH, Calif.

Loan Agreement, dated as of December 14, 2021, by and among Evolus, Inc. (as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numb

Evolus Reports Third Quarter 2021 Results and Provides Business Update •Record Quarter: U.S. Net Revenue Grew 58% Year-over-Year to $26.7 Million •$107.8 Million Cash Position at Quarter-End •Initiated Jeuveau® “Extra Strength” Phase II Clinical Prog

Evolus Reports Third Quarter 2021 Results and Provides Business Update ?Record Quarter: U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLU

EOLS / Evolus Inc / Alphaeon 1 LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Evolus, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 30052C107 (CUSIP Num

EOLS / Evolus Inc / Alphaeon 1 LLC - SC 13D/A Activist Investment

SC 13D/A 1 eolssc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Evolus, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numbe

Evolus Reports Second Quarter 2021 Results and Provides Business Update Record Quarter: Net Revenue grew 235% Year-over-Year to $26.1 Million Exceeded Annualized Revenue Run Rate Goal of $100 Million Low Q2 Cash Burn Resulting in $131.7 Million Cash

Evolus Reports Second Quarter 2021 Results and Provides Business Update Record Quarter: Net Revenue grew 235% Year-over-Year to $26.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, IN

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

Evolus Reports First Quarter 2021 Results and Provides Business Update Q1 2021 Net Revenues of $12.2 million, Despite Half-Quarter ITC Impact Full Resolution of International Trade Commission (ITC) Case Restructured Balance Sheet with March 31, 2021

Evolus Reports First Quarter 2021 Results and Provides Business Update Q1 2021 Net Revenues of $12.

Convertible Promissory Note Conversion Agreement, dated March 23, 2021, by and between Evolus, Inc. and Daewoong Pharmaceutical Co. Ltd.

EVOLUS, INC. CONVERTIBLE PROMISSORY NOTE CONVERSION AGREEMENT This Convertible Promissory Note Conversion Agreement (this ?Agreement?) is made as of March 23, 2021, by and among Evolus, Inc., a Delaware corporation (the ?Company?), and Daewoong Pharmaceutical Co., Ltd. (the ?Holder?). RECITALS A. The Holder holds a Convertible Promissory Note, dated as of July 30, 2020 in the original principal su

Settlement and License Agreement, dated February 18, 2021, by and among Evolus, Inc., Allergan Limited, Allergan, Inc., Allergan Pharmaceuticals Ireland and Medytox, Inc.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.

Share Issuance Agreement, dated February 18, 2021, by and between Evolus Inc. and Medytox, Inc.

EVOLUS, INC. SHARE ISSUANCE AGREEMENT This Share Issuance Agreement (this ?Agreement?) is made as of February 18, 2021, by and among Evolus, Inc., a Delaware corporation (the ?Company?), and Medytox, Inc., a company organized under the laws of Korea (?Medytox?). RECITALS A. Concurrently with the entrance by the Company and Medytox into this Agreement, the Company and Medytox are also entering into

Registration Rights Agreement, dated February 18, 2021, by and between Evolus Inc. and Medytox, Inc. (incorporated by reference to Exhibit 4.1 to the Registrant's Form 10-Q filed on May 12, 2021)..

EXECUTION REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is dated as of February 18, 2021 (the ?Effective Date?) by and among Evolus, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, I

Confidential Settlement and Release Agreement, dated March 23, 2021, by and between Evolus, Inc. and Daewoong Pharmaceutical Co. Ltd.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.

Settlement and License Agreement, dated February 18, 2021, by and between Evolus, Inc. and Medytox, Inc.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.

Third Amendment to Supply Agreement, dated March 23, 2021, by and between Evolus, Inc. and Daewoong Pharmaceutical Co. Ltd.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number

, by and between Evolus, Inc. and SVB Leerink LLC, Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co., as representatives of the underwriters.

EVOLUS, INC. (a Delaware corporation) 9,000,000 Shares of Common Stock UNDERWRITING AGREEMENT April 21, 2021 SVB Leerink LLC Stifel, Nicolaus & Company, Incorporated Cantor Fitzgerald & Co. as Representatives of the several Underwriters c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, MA 02110 c/o Stifel, Nicolaus & Company, Incorporated 787 Seventh Avenue New York, NY 10019 c/o Cantor F

Company’s Proxy Statement for its 2021 Annual Meeting of Stockholders filed with the Securities and Exchange Commission (the “SEC”) on April 26, 2021

DEF 14A 1 eols2020proxy.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 1

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number

- DEFA14A

DEFA14A 1 eols2020proxynotice.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by

9,000,000 shares Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-230466 333-255423 PROSPECTUS SUPPLEMENT (to Prospectus dated April 15, 2019) 9,000,000 shares Common Stock This is a public offering of 9,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Market, or Nasdaq, under the trading symbol ?EOLS.? On April 21, 2021, the last reported sale price of ou

- S-3MEF

As filed with the Securities and Exchange Commission on April 21, 2021 Registration No.

SUBJECT TO COMPLETION, DATED APRIL 21, 2021

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230466 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell and are

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCH

SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Evolus, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 30052C107 (CUS

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number

File No.

As filed with the Securities and Exchange Commission on March 26, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Evolus, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1385614 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer I

Up to $75,000,000 Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230466 PROSPECTUS SUPPLEMENT (to Prospectus dated April 15, 2019) Up to $75,000,000 Common Stock We have entered into an open market sales agreement with SVB Leerink LLC, or SVB Leerink, relating to the sale of our common stock offered by this prospectus supplement. In accordance with the terms of the sales agreement, under th

Sales Agreement, dated March 26, 2021, by and between Evolus, Inc. and SVB Leerink LLC as Sales Agent.

EVOLUS, INC. Shares of Common Stock ($0.00001 par value per share) SALES AGREEMENT March 26, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Evolus, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Leerink LLC (the ?Agent?), as follows: 1.Issuance and Sale of Shares. The Company agrees that,

description of our common stock contained in Exhibit 4.3 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 25, 2021

Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following is a summary of the rights of our common stock and preferred stock, certain provisions of our certificate of incorporation and our bylaws, and applicable law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and bylaws, copies of which are filed as exhibits to o

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, INC. (Exact name

Evolus Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau® Pro Forma Cash Position of $57 Million at December 31, 20201

Evolus Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update Q4 2020 Net Revenue $20.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number

Evolus Strengthens Balance Sheet Through A $25.5 Million Cash Infusion And Elimination of $127.4 Million of Debt and Milestone Payments Pro Forma Cash Position of $57 Million at December 31, 20201

Evolus Strengthens Balance Sheet Through A $25.5 Million Cash Infusion And Elimination of $127.4 Million of Debt and Milestone Payments Pro Forma Cash Position of $57 Million at December 31, 20201 Newport Beach, Calif., March 23, 2021 - Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced several tra

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Evolus, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) (

7,4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Evolus, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 30052C107 (CUSIP Number) February 18, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Num

Evolus Announces Promotion of Crystal Muilenburg to Chief Marketing Officer

Evolus Announces Promotion of Crystal Muilenburg to Chief Marketing Officer Newport Beach, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Num

Evolus Announces Preliminary, Unaudited, Fourth Quarter and Full Year 2020 Net Revenue Q4 2020 Net Revenue of $20.6 Million Increased 16% Over Q3 2020

Evolus Announces Preliminary, Unaudited, Fourth Quarter and Full Year 2020 Net Revenue Q4 2020 Net Revenue of $20.

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Num

### AbbVie: Media: Adelle Infante +1 (847) 938-8745 [email protected] Evolus: Media: Crystal Muilenburg Vice President, Corporate Communications & Public Relations +1-949-284-4506 [email protected] Investors: Liz Shea +1 (847) 935-2211 liz.she

AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation NORTH CHICAGO, Ill.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Num

Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Evolus, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) (CUSIP Number)

Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2021 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numbe

Payoff Letter, dated January 4, 2021, from Oxford Finance LLC to Evolus, Inc.

January 4, 2021 Lauren Silvernail Chief Financial Officer EVOLUS, INC. 520 Newport Center Drive, Suite 1200 Newport Beach CA 92660 Dear Ms. Silvernail: We refer to the Loan and Security Agreement dated as of March 15, 2019 (as the same may from time to time have been amended, restated, or otherwise modified, the “Loan Agreement”) among Oxford Finance LLC (“Oxford”), as collateral agent (in such ca

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Num

Evolus Provides Update on United States International Trade Commission (ITC) Case Section 337 Violation Partially Affirmed by ITC Jeuveau® Sales and Marketing Continue Under Bond All Options Under Review to Resolve Legal Dispute

EX-99.1 2 ex991.htm EX-99.1 Evolus Provides Update on United States International Trade Commission (ITC) Case Section 337 Violation Partially Affirmed by ITC Jeuveau® Sales and Marketing Continue Under Bond All Options Under Review to Resolve Legal Dispute Newport Beach, Calif., December 16, 2020 – Evolus, Inc. (NASDAQ: EOLS) today announced that the United States International Trade Commission (I

Regulation FD Disclosure - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2020 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Num

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numb

Evolus Reports Third Quarter 2020 Results and Provides Business Update Q3 2020 Net Revenue of $17.7 Million; 34 Percent Increase Over Q3 2019 Cash1 Position Increased Over Q2 2020 to $110.1 Million

Evolus Reports Third Quarter 2020 Results and Provides Business Update Q3 2020 Net Revenue of $17.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLU

Regulation FD Disclosure - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2020 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numb

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 EVOLUS, IN

Evolus Reports Second Quarter 2020 Results and Provides Business Update Q2 2020 Net Revenue $7.8 Million, Up from $2.3 Million in Q2 2019 $40 Million Convertible Note Financing Closed in July 2020 Pro Forma June 30, 2020 Cash1 Position of $124.8 Mill

Evolus Reports Second Quarter 2020 Results and Provides Business Update Q2 2020 Net Revenue $7.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Numbe

Subordination Agreement. dated July 6, 2020, by and among Evolus, Inc., Oxford Finance, LLC and Daewoong Pharmaceutical Co. Ltd.

SUBORDINATION AGREEMENT This Subordination Agreement (the “Agreement”) is made as of July 6, 2020, by and between Daewoong Pharmaceutical Co.

Convertible Promissory Note by and between Evolus, Inc. and Daewoong Pharmaceuticals Co. Ltd.

THIS CONVERTIBLE NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES.

Evolus Provides Update on International Trade Commission (ITC) Case Commission to Review Case; Final Determination Targeted for November 2020 Jeuveau® Launch and Product Supply Unaffected by Initial Determination

Evolus Provides Update on International Trade Commission (ITC) Case Commission to Review Case; Final Determination Targeted for November 2020 Jeuveau® Launch and Product Supply Unaffected by Initial Determination Newport Beach, Calif.

Convertible Promissory Note Purchase Agreement, dated July 6, 2020, by and between Evolus, Inc. and Daewoong Pharmaceutical Co. Ltd.

EVOLUS, INC. CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT This Convertible Promissory Note Purchase Agreement (this “Agreement”) is made as of July 6, 2020, by and among Evolus, Inc., a Delaware corporation (the “Company”), and Daewoong Pharmaceutical Co., Ltd. (the “Purchaser”). RECITALS A. The Company and the Purchaser previously entered into that certain License and Supply Agreement dated Sep

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2020 EVOLUS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38381 46-1385614 (State or other jurisdiction of incorporation) (Commission File Number)

Evolus Strengthens Balance Sheet; Secures $40 Million Investment Pro Forma Cash1 Position of $125 Million at June 30, 2020

Evolus Strengthens Balance Sheet; Secures $40 Million Investment Pro Forma Cash1 Position of $125 Million at June 30, 2020 Newport Beach, Calif.